244 related articles for article (PubMed ID: 29427323)
1. Androgen receptor dampens tissue factor expression via nuclear factor-κB and early growth response protein 1.
Hoesel B; Mussbacher M; Dikorman B; Salzmann M; Assinger A; Hell L; Thaler J; Basílio J; Moser B; Resch U; Paar H; Mackman N; Schmid JA
J Thromb Haemost; 2018 Apr; 16(4):749-758. PubMed ID: 29427323
[TBL] [Abstract][Full Text] [Related]
2. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
[TBL] [Abstract][Full Text] [Related]
3. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
Ko S; Shi L; Kim S; Song CS; Chatterjee B
Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
[TBL] [Abstract][Full Text] [Related]
4. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
5. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
6. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Jin RJ; Lho Y; Connelly L; Wang Y; Yu X; Saint Jean L; Case TC; Ellwood-Yen K; Sawyers CL; Bhowmick NA; Blackwell TS; Yull FE; Matusik RJ
Cancer Res; 2008 Aug; 68(16):6762-9. PubMed ID: 18701501
[TBL] [Abstract][Full Text] [Related]
7. PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
Li Y; Lv L; Ye M; Xie N; Fazli L; Wang Y; Wang W; Yang S; Ni Q; Chen J; Guo X; Zhao Y; Xue G; Sha J; Dong X; Zhang L
Oncogene; 2024 May; 43(21):1631-1643. PubMed ID: 38589675
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
10. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
13. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers.
Xu B; Tang G; Xiao C; Wang L; Yang Q; Sun Y
Int J Clin Exp Pathol; 2014; 7(6):2883-93. PubMed ID: 25031707
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
17. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
19. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
